Tepilamide fumarate is under clinical development by Dr. Reddy’s Laboratories and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tepilamide fumarate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tepilamide fumarate overview

Tepilamide fumarate (XP-23829) is under development for the treatment of moderate to severe chronic plaque psoriasis. The drug candidate is administered orally in the form of tablet. XP-23829 is a new chemical entity and is a pro-drug of methylhydrogen fumarate (MHF), a fumaric acid monomethyl ester. The drug candidate is developed based on transported prodrug technology. The technology utilizes the body's natural mechanisms for actively transporting nutrients through cellular barriers. The drug candidate acts by targeting the mutated kelch like ECH associated protein 1 (KEAP1).

It was also under development for the treatment of patients with relapsing remitting multiple sclerosis (RRMS).

Dr. Reddy’s Laboratories overview

Dr. Reddy’s Laboratories (Dr. Reddy’s) is a pharmaceutical company that manufactures and markets generic formulations, active pharmaceutical ingredients (APIs), biosimilars and proprietary products. The company’s generic products are indicated for the treatment of gastrointestinal disorders, various cancer types, cardiovascular diseases, pain, central nervous system disorders, infectious diseases, and pediatric diseases. The company also develops and markets generic biosimilar products. Its pipeline includes New Chemical Entities (NCEs) that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation. The company markets products in the US, Europe, Latin America, and Asia. Dr. Reddy’s is headquartered in Hyderabad, Telangana, India.

For a complete picture of Tepilamide fumarate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.